| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Change in fair value of warrant liability | 0 | - |
| Change in fair value of forward contract liability | 0 | - |
| Commitment fee payable | 0 | - |
| Payable to parent | 0 | - |
| Change in fair value of sepa put option liability | 23 | - |
| Change in fair value of convertible debt | -963 | -117 |
| Non-cash original discount on convertible debt | 625 | - |
| Stock-based compensation expense | 1,984 | 1,280 |
| Amortization of operating lease right-of-use asset | 420 | 254 |
| Prepaid expenses | 148 | 1,108 |
| Accounts payable and accrued expenses | -1,378 | -646 |
| Other current assets | -18 | -18 |
| Other assets | 48 | 48 |
| Operating lease liability | -420 | -250 |
| Net loss | -15,402 | - |
| Depreciation expense | 178 | 113 |
| Net cash used in operating activities | -13,231 | -9,259 |
| Purchases of property and equipment | 262 | 256 |
| Net cash used in investing activities | -262 | -256 |
| Repayments of short-term borrowing | 0 | 0 |
| Proceeds from issuance of common stock, net of direct costs | 0 | 0 |
| Proceeds from short-term convertible debt | 4,375 | 4,375 |
| Net cash provided by financing activities | 4,375 | 4,375 |
| Net decrease in cash and cash equivalents | -9,118 | -5,140 |
| Cash and cash equivalents at beginning of period | 13,985 | - |
| Cash and cash equivalents at end of period | 4,867 | - |
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)